THC Farmaceuticals, Inc. (CBDG)
USD 0.01
(8.0%)
USD 0.01
(8.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 142.09 Thousand USD | 0.0% |
| 2022 | 142.09 Thousand USD | -75.82% |
| 2021 | 587.66 Thousand USD | 6.58% |
| 2020 | 551.39 Thousand USD | -49.27% |
| 2019 | 1.08 Million USD | 13.35% |
| 2018 | 958.96 Thousand USD | -0.07% |
| 2017 | 959.67 Thousand USD | 0.7% |
| 2016 | 952.97 Thousand USD | 0.0% |
| 2014 | 96.17 USD | 45.71% |
| 2013 | 66.00 USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2022 Q3 | 594.97 Thousand USD | 0.59% |
| 2022 Q1 | 592.44 Thousand USD | 0.0% |
| 2022 Q2 | 591.45 Thousand USD | -0.17% |
| 2021 FY | 587.66 Thousand USD | 6.58% |
| 2020 FY | 551.39 Thousand USD | -49.27% |
| 2020 Q1 | 522.29 Thousand USD | 0.0% |
| 2019 FY | 1.08 Million USD | 13.35% |
| 2019 Q2 | 1 Million USD | 0.0% |
| 2019 Q3 | 1.04 Million USD | 4.09% |
| 2018 FY | 958.96 Thousand USD | -0.07% |
| 2017 FY | 959.67 Thousand USD | 0.7% |
| 2016 FY | 952.97 Thousand USD | 0.0% |
| 2015 Q3 | 700.98 USD | 7.31% |
| 2015 Q2 | 653.24 USD | 3576.29% |
| 2015 Q1 | 17.77 USD | -81.52% |
| 2014 Q1 | 79.89 USD | 21.06% |
| 2014 Q4 | 96.17 USD | 8.51% |
| 2014 FY | 96.17 USD | 45.71% |
| 2014 Q3 | 88.62 USD | 5.81% |
| 2014 Q2 | 83.76 USD | 4.84% |
| 2013 FY | 66.00 USD | 0.0% |
| 2013 Q2 | 57.43 USD | 0.0% |
| 2013 Q4 | 66.00 USD | 6.25% |
| 2013 Q3 | 62.11 USD | 8.16% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -417.971% |
| Arch Therapeutics, Inc. | 9.46 Million USD | 98.499% |
| Evofem Biosciences, Inc. | 72.47 Million USD | 99.804% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | 82.431% |
| Rebus Holdings, Inc. | 5.24 Million USD | 97.289% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 99.759% |
| Qrons Inc. | 1.48 Million USD | 90.455% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 1.22 Million USD | 88.412% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 99.81% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -217.914% |
| Skye Bioscience, Inc. | 14.07 Million USD | 98.99% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 99.733% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | 98.517% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | 66.294% |
| SQZ Biotechnologies Company | 50.03 Million USD | 99.716% |
| Intellipharmaceutics International Inc. | 12 Million USD | 98.817% |
| Propanc Biopharma, Inc. | 3.85 Million USD | 96.311% |
| Mesoblast Limited | 188.44 Million USD | 99.925% |
| Marizyme, Inc. | 26.67 Million USD | 99.467% |
| Genus plc | 485 Million USD | 99.971% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | 97.568% |
| Pharming Group N.V. | 244.07 Million USD | 99.942% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | 92.931% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | 94.353% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | 96.261% |
| ContraFect Corporation | 32.53 Million USD | 99.563% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | 92.828% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | 96.288% |
| IMV Inc. | 37.93 Million USD | 99.625% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | 98.794% |
| MultiCell Technologies, Inc. | 1617.67 USD | -8683.93% |
| ONE Bio Corp. | 27.49 Million USD | 99.483% |
| Accustem Sciences Inc. | 1.07 Million USD | 86.834% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 99.816% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 2.11 Million USD | 93.282% |
| Q BioMed Inc. | 8.13 Million USD | 98.253% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 99.829% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | 97.239% |
| Biomind Labs Inc. | 1.49 Million USD | 90.518% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 99.88% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | 98.429% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | 99.228% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | 90.09% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | 29.347% |
| Curative Biotechnology, Inc. | 5.74 Million USD | 97.527% |
| GB Sciences, Inc. | 5.41 Million USD | 97.377% |
| Alpha Cognition Inc. | 7.16 Million USD | 98.017% |
| HST Global, Inc. | 593.59 Thousand USD | 76.062% |
| CSL Limited | 18.62 Billion USD | 99.999% |
| Wesana Health Holdings Inc. | 1.25 Million USD | 88.715% |
| Halberd Corporation | 728.71 Thousand USD | 80.501% |
| Enzolytics Inc. | 365.26 Million USD | 99.961% |
| Agentix Corp. | 2.51 Million USD | 94.34% |
| Resverlogix Corp. | 67.39 Million USD | 99.789% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | 83.058% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 444.95 Million USD | 99.968% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | 91.71% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | 99.426% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | 98.806% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | 96.123% |
| AVAX Technologies, Inc. | 3.99 Million USD | 96.442% |
| Zenith Capital Corp. | 27.56 Thousand USD | -415.416% |
| Genscript Biotech Corporation | 1.32 Billion USD | 99.989% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | 40.46% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | 96.195% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | 79.129% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | 94.76% |
| Kadimastem Ltd | 3.5 Million USD | 95.946% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -112.307% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 50.26 Million USD | 99.717% |
| BioStem Technologies, Inc. | 15.9 Million USD | 99.107% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 464.69 Thousand USD | 69.422% |
| LadRx Corporation | 2.2 Million USD | 93.543% |
| Cell Source, Inc. | 15.8 Million USD | 99.101% |
| Regen BioPharma, Inc. | 5.45 Million USD | 97.396% |
| Regen BioPharma, Inc. | 5.45 Million USD | 97.396% |
| NovAccess Global Inc. | 7.86 Million USD | 98.192% |
| Affymax, Inc. | 8.87 Million USD | 98.398% |
| Itoco Inc. | 1.65 Million USD | 91.405% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | 93.074% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | 97.651% |
| Mobile Lads Corp. | 1.31 Million USD | 89.182% |
| CytoDyn Inc. | 127.89 Million USD | 99.889% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -239.948% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | 90.928% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | 98.714% |
| SYBLEU INC | 681.41 Thousand USD | 79.147% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | 97.671% |
| International Stem Cell Corporation | 5.27 Million USD | 97.307% |
| Bioxytran, Inc. | 3.24 Million USD | 95.627% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | 77.294% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | 96.922% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | 99.653% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | 99.362% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | 92.984% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | 97.406% |
| Neutra Corp. | 973.52 Thousand USD | 85.404% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | 99.51% |
| PureTech Health plc | 125.58 Million USD | 99.887% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | 96.218% |
| IXICO plc | 1.9 Million USD | 92.522% |
| IntelGenx Technologies Corp. | 20.52 Million USD | 99.308% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 99.862% |
| CSL Limited | 18.62 Billion USD | 99.999% |
| Cellectis S.A. | 249.36 Million USD | 99.943% |